Sutro Biopharma, Inc.
STRONASDAQHealthcare● Active
$25.41
$-0.68(-2.61%)
Market Cap$245899075
P/E Ratio—
52W High$43.85
52W Low$6.7
Sutro Biopharma, Inc. (STRO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
STRO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$2.94
Est. -$2.32 · -26.7%
Revenue
$0.01B
Est. $0.01B · +63.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
STRO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.12
Rev. $4.47B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.12
Rev. Est.$4.47B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$2.17 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$2.32 | -$2.94 | -26.7% | $0.01B | $0.01B | +63.3% |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$8.16 | -$5.29 | +35.2% | $0.01B | $0.01B | +25.8% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$4.20 | -$6.70 | -59.5% | $0.01B | $0.01B | -4.4% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.39 | -$0.14 | +64.1% | $0.06B | $0.01B | +616.6% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.63 | -$0.91 | -44.4% | $0.02B | $0.01B | +16.0% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -$0.86 | -$0.89 | -3.5% | $0.01B | $0.01B | +21.8% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.74 | -$0.59 | +20.3% | $0.01B | $0.01B | -30.1% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$2.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$2.94
EPS Est.
-$2.32
EPS Surpr.
-26.7%
Revenue
$0.01B
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$5.29
EPS Est.
-$8.16
EPS Surpr.
+35.2%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$6.70
EPS Est.
-$4.20
EPS Surpr.
-59.5%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.39
EPS Surpr.
+64.1%
Revenue
$0.06B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.91
EPS Est.
-$0.63
EPS Surpr.
-44.4%
Revenue
$0.02B
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$0.89
EPS Est.
-$0.86
EPS Surpr.
-3.5%
Revenue
$0.01B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.59
EPS Est.
-$0.74
EPS Surpr.
+20.3%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-3.31 | $-1.95 | $0.07 | 2 |
| Q3 FY2027 | $-3.38 | $-1.99 | $0.07 | 1 |
| Q2 FY2027 | $-3.57 | $-2.11 | $0.07 | 1 |
| Q1 FY2027 | $-3.69 | $-2.18 | $0.07 | 2 |
| Q4 FY2026 | $-3.27 | $-1.93 | $0.07 | 2 |
| Q3 FY2026 | $-2.59 | $-2.04 | $-1.41 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -26.7% | $39.60 | $38.42 | -2.98% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +35.2% | $20.68 | $21.33 | +3.14% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -59.5% | $9.84 | $9.42 | -4.27% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +64.1% | $8.18 | $8.00 | -2.20% |
| ▼ Q2 FY2025 | May 8, 2025 | -44.4% | $9.93 | $9.58 | -3.52% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -3.5% | $13.40 | $12.50 | -6.72% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +20.3% | $40.80 | $39.60 | -2.94% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +22.4% | $32.40 | $32.20 | -0.62% |
Q2 FY2026-2.98%
Report Date
May 14, 2026
EPS Beat/Miss
-26.7%
Price Before
$39.60
Price After
$38.42
Q1 FY2026+3.14%
Report Date
Mar 23, 2026
EPS Beat/Miss
+35.2%
Price Before
$20.68
Price After
$21.33
Q4 FY2025-4.27%
Report Date
Nov 6, 2025
EPS Beat/Miss
-59.5%
Price Before
$9.84
Price After
$9.42
Q3 FY2025-2.20%
Report Date
Aug 7, 2025
EPS Beat/Miss
+64.1%
Price Before
$8.18
Price After
$8.00
Q2 FY2025-3.52%
Report Date
May 8, 2025
EPS Beat/Miss
-44.4%
Price Before
$9.93
Price After
$9.58
Q1 FY2025-6.72%
Report Date
Mar 13, 2025
EPS Beat/Miss
-3.5%
Price Before
$13.40
Price After
$12.50
Q4 FY2024-2.94%
Report Date
Nov 13, 2024
EPS Beat/Miss
+20.3%
Price Before
$40.80
Price After
$39.60
Q3 FY2024-0.62%
Report Date
Aug 13, 2024
EPS Beat/Miss
+22.4%
Price Before
$32.40
Price After
$32.20
Avg Beat Reaction-0.66%
Avg Miss Reaction-4.37%
Beat Rate4 / 8 quarters
Largest Move-6.72% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: STRO ends December
Sutro Biopharma, Inc. (STRO) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-2.94 — missing the analyst consensus of $-2.32 by -26.7%. The next STRO earnings date is expected around September 1, 2026.
Each quarter, investors track STRO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. STRO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
STRO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
STRO earnings · 5 questionsSutro Biopharma, Inc.'s next earnings report is expected around September 1, 2026. STRO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; STRO historically reports after market close (AMC).
STRO earnings datewhen is STRO earningsSTRO next earnings datewhen does STRO report earningsSTRO earnings calendar
▸ Source: FMP · Sutro Biopharma, Inc. SEC filings · US GAAP · Sutro Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026